▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Samsung Bioepis on track to launching first Herceptin biosimilar in Europe

  • PUBLISHED :September 18, 2017 - 17:15
  • UPDATED :October 11, 2017 - 15:08
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Samsung Bioepis has become the first company to secure Europe’s backing of its copy of Roche’s blockbuster breast cancer therapy Herceptin, marking a milestone for the South Korean drugmaker, which specializes in making cheaper copies of complex biologic drugs known as biosimilars.

The European Medicines Agency’s Committee for Medicinal Products for Human Use on Sept. 15 recommended the approval of Samsung’s Herceptin-referencing biosimilar Ontruzant. It is the first biosimilar copy of Herceptin to obtain such backing in Europe.

 

A Samsung Bioepis employee works at a laboratory inside the company’s headquarters in Songdo, Incheon. Samsung Bioepis.



According to protocol, the European Commission is set to follow the EMA’s opinion by issuing marketing approval in around two to three months, upon which Samsung Bioepis can begin selling Ontruzant in European markets. Samsung’s partner Merck & Co. is set to take charge of the drug’s marketing.

The EMA’s endorsement sets Samsung Bioepis on track to bringing the first biosimilar version of Herceptin (trastuzumab) to Europe and challenging sales of Herceptin, which generated around $6.8 billion in global revenue for Roche in 2016.

“We are proud to see Ontruzant become the first trastuzumab biosimilar recommended for approval in Europe, where breast cancer remains the most common form of cancer affecting women,” said Samsung Bioepis CEO Ko Han-sung. 

“If approved, we hope Ontruzant will play an important role in expanding patient access to trastuzumab across the region,” Ko said.

Samsung Bioepis is closely being followed by competitors, including Korea’s Celltrion as well as Mylan and Biocon, which have each submitted their own Herceptin copy for approval by the EMA. However, Mylan and Biocon are reportedly facing delays in approval due to manufacturing issues. 

The EMA’s backing of Ontruzant also signals a new feat for Samsung Bioepis’ drug pipeline, as it is the firm’s first cancer-targeting drug to be close to regulatory approval.

Samsung has so far secured approval for three biosimilar drugs in Europe, referencing Remicade, Enbrel and Humira. They are all anti-TNF therapies targeting autoimmune diseases such as rheumatoid arthritis and Crohn’s disease.

The development on Sept. 15 also led local analysts to raise their target stock price for Samsung BioLogics, the parent company of Samsung Bioepis, on Sept. 18. Shares of Samsung BioLogics hit an all-time high of 333,500 won before closing at 328,500 on the day, up 0.61 percent from the previous trading day.
 
Samsung Bioepis was founded in 2012 as a joint venture between contract drug manufacturer Samsung BioLogics and US drugmaker Biogen. Biogen holds a 5.4 percent stake in Bioepis, while Samsung BioLogics owns the remainder of the shares 

By Sohn Ji-young/The Korea Herald (jys@heraldcorp.com)

EDITOR'S PICKS